XML 20 R10.htm IDEA: XBRL DOCUMENT v3.24.4
Revenue from Contracts with Customers
 6 Months Ended
Oct. 31, 2024
Revenue from Contract with Customer [Abstract]  
Revenue from Contracts with Customers Revenue from Contracts with Customers
Oncology Services Revenue
The following table represents disaggregated revenue for the three and six months ended October 31, 2024 and 2023:
Three Months Ended
October 31,		Six Months Ended October 31,
 2024202320242023
Pharmacology services$12,498 $10,876 $25,567 $22,735 
Other TOS revenue991 697 1,983 1,381 
Personalized oncology services— — — 18 
Total oncology services revenue$13,489 $11,573 $27,550 $24,134 
Other Translational Oncology Solutions ("TOS") revenue represents additional services provided to the Company's pharmaceutical and biotechnology customers, specifically flow cytometry services and software-as-a-service ("SaaS") provided via our Lumin Bioinformatics software ("Lumin").